Perspectives on Selected Hemophilia Research Presented at ISTH 2025: Nonfactor Replacement Therapies

To participate in this activity, please:

The treatment of persons with hemophilia continues to evolve, with important advancements that address limitations with factor replacement such as diminished efficacy in patients with inhibitors and the burden of frequent intravenous administration. This 30-minute activity delves into the latest research presented at ISTH 2025, highlighting rebalancing agents and factor VIII mimetics. In addition to discussing details of each trial, Dr. von Drygalski shares her thoughts about its importance and relevance to clinical practice.

This content is also available as a podcast:  You may listen here.

Course Credit:

0.50 AAPA Category I CME Credit
0.50 ACPE Contact Hours
0.50 AMA PRA Category 1 CreditsTM
0.50 ANCC Contact Hours
0.50 CA-BRN Contact Hours

Dates:

Opens: 2025-08-13
Closes: 2026-08-13

Target Audience:

This activity was developed for hematologists, hematology nurse practitioners, hematology physician associates, pharmacists, and other clinicians involved in the management of patients with hemophilia.

This activity is supported by an educational grant from Novo Nordisk, Inc.

    Presenting Faculty

  • Annette von Drygalski, MD, PharmD, RMSK  headshot

    Annette von Drygalski, MD, PharmD, RMSK

    Professor of Clinical Medicine
    Director, Center for Bleeding and Clotting Disorders
    Associate Director, Center of Excellence for Hereditary Hemorrhagic Telangiectasia
    Program Director, Coagulation Medicine Fellowship
    Associate Program Director, Hematology Fellowship
    University of California, San Diego
    San Diego, California